All In Biotech

Drug Trial Radar · NCT02831660

CU Programme of Idarucizumab for Japanese Patients

A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures

Last checked: Nov 20, 2026Latest source record: Mar 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1

Actual

Start

Jul 22, 2016

Primary completion

Sep 16, 2016

Study completion Sep 16, 2016

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.

Conditions

  • Hemorrhage

Interventions

  • idarucizumabDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Drug-related Adverse EventsTime frame: from first drug administration until 5 days after last drug administration, up to 6 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fukuoka Tokushukai Medical Center

    Fukuoka, Kasuga, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.